[Antibody therapy in cancer].

By H. Komatsu. Nihon rinsho. Japanese journal of clinical medicine, 2010

871 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses (2018, unknown): “Logical Operation with the SUPRA CAR System Antigen escape is a major challenge for targeted cancer therapies (Scott et al., 2012), including adoptive T cell therapies (Hegde et al.”
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients (2013, background): “penetrance and drug concentration in the tumor, antibody stability, and receptor occupancy (39).”
AbDesign: an algorithm for combinatorial backbone design guided by natural conformations and sequences (2015, background): “36–38 To be sure, in certain systems selection methods were developed to isolate antibodies that bind specific epitopes on target molecules39–43; yet these capabilities are challenging and rely on specific properties of the target molecule, such as naturally high antigenic variability outside the…”
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies (2014, background): “Thus, monoclonal antibody-based cancer therapy has been established and becomes one of the most efficient and safe strategies for cancer treatment [5].”